Ionis Pharmaceuticals (IONS) Tops Q2 EPS by 28c; reaffirms guidance

Ionis Pharmaceuticals (NASDAQ: IONS) reported Q2 EPS of ($0.60), $0.28 better than the analyst estimate of ($0.88). Revenue for the quarter came in at $188 million versus the consensus estimate of $140.11 million.

For earnings history and earnings-related data on Ionis Pharmaceuticals (IONS) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Azitra, Inc. (AZTR) Tops Q2 EPS by 54c
• UBS Reiterates Buy Rating on Sysco (SYY) Following Trip to Company Headquarters